Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1379-1388

  Hsu, Lih Ching ^a   Durrant, David E ^b   Huang, Ching Chun ^a   Chi, Nai Wen ^c   Baruchello, Riccardo ^d   Rondanin, Riccardo ^d   Rullo, Cinzia ^d   Marchetti, Paolo ^d   Grisolia, Giuseppina ^d   Simoni, Daniele ^d   Lee, Ray M ^e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF FERRARA   (Italy)

^e Lestoni Corp   (United States)

Author keywords

Anticancer; Hemiasterlins; Stilbene 5c; Tubulin; Vincristine

Indexed keywords

3,4',5 TRIMETHOXY 3' AMINOSTILBENE; BF 65; BF 78; CYCLIN DEPENDENT KINASE 1; HEMIASTERLIN DERIVATIVE; KINESIN 5; MONASTROL; NOCODAZOLE; PACLITAXEL; PROTEIN BCL 2; STILBENE DERIVATIVE; TUBULIN MODULATOR; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CENTROSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MITOSIS SPINDLE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; DRUG SYNERGISM; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KINESIN; MICE; MICROTUBULES; MITOTIC SPINDLE APPARATUS; OLIGOPEPTIDES; POLYMERIZATION; SIGNAL TRANSDUCTION; STILBENES; TREATMENT OUTCOME; TUBULIN; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866737041     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9702-9     Document Type: Article

References (37)

1. Jordan MA, Wilson L. (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265. doi:10.1038/nrc1317
2. Rowinsky EK, Calvo E. (2006) Novel agents that target tublin and related elements. Semin Oncol 33:421-435. doi:10.1053/j. seminoncol.2006.04.006
3. Stevenson JP, Rosen M, Sun W et al. (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:4428-4438. doi:10.1200/JCO.2003.12.986
4. Cooney MM, Radivoyevitch T, Dowlati A et al. (2004) Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10:96-100. doi:10.1158/1078-0432. CCR-0364-3
5. Rustin GJ, Galbraith SM, Anderson H et al. (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21:2815-2822. doi:10.1200/JCO.2003.05.185
6. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. (2003) Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21:2823-2830. doi:10.1200/JCO.2003.05. 186
7. Blakey DC, Westwood FR, Walker M et al. (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974-1983
8. Beerepoot LV, Radema SA, Witteveen EO et al. (2006) Phase I clinical evaluation of weekly administration of the novel vasculartargeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491-1498. doi:10.1200/JCO.2005.02.7458
9. Nabha SM, Mohammad RM, Dandashi MH et al. (2002) Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly. (ADP-ribose) polymerase cleavage. Clin Cancer Res 8:2735-2741
10. Jackson JR, Patrick DR, Dar MM, Huang PS. (2007) Targeted antimitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7:107-117. doi:10.1038/nrc2049
11. Malumbres M. (2006) Therapeutic opportunities to control tumor cell cycles. Clin Transl Oncol 8:399-408. doi:10.1007/s12094-006-0193-7
12. Swanton C. (2004) Cell-cycle targeted therapies. Lancet Oncol 5:27-36. doi:10.1016/S1470-2045(03)01321-4
13. Dai Y, Grant S. (2004) Small molecule inhibitors targeting cyclindependent kinases as anticancer agents. Curr Oncol Rep 6:123-130. doi:10.1007/s11912-004-0024-3
14. Manfredi MG, Ecsedy JA, Meetze KA et al. (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 104:4106-4111. doi:10.1073/pnas.0608798104
15. Tyler RK, Shpiro N, Marquez R, Eyers PA. (2007) VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle 6:2846-2854. doi:10.4161/cc.6.22.4940
16. McInnes C, Mezna M, Fischer PM. (2005) Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem 5:181-197
17. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286:971-974. doi:10.1126/science.286.5441.971
18. Tang PA, Siu LL, Chen EX et al. (2008) Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 26:257-264. doi:10.1007/s10637-007-9098-8
19. Lee CW, Bélanger K, Rao SC et al. (2008) A phase II study of ispinesib. (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 26:249-255. doi:10.1007/s10637-007-9097-9
20. Valentine MT, Fordyce PM, Block SM. (2006) Eg5 steps it up! Cell Div 1:31. doi:10.1186/1747-1028-1-31
21. Bergnes G, Brejc K, Belmont L. (2005) Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem 5:127-145. doi:10.2174/ 1568026053507697
22. Cao TM, Durrant D, Tripathi A et al. (2008) Stilbene derivatives that are colchicine site microtubule inhibitors have anti-leukemic activity and minimal systemic toxicity. Am J Hematol 83:390-397. doi:10.1002/ajh.21104
23. Bai R, Durso NA, Sackett DL, Hamel E. (1999) Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry 38:14302-14310. doi:10.1021/bi991323e
24. Loganzo F, Discafani CM, Annable T et al. (2003) HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 63:1838-1845
25. Nieman JA, Coleman JE, Wallace DJ et al. (2003) Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues. J Nat Prod 66:183-199. doi:10.1021/np020375t
26. Perez EA, Hillman DW, Fishkin PA et al. (2005) Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs 23:257-261. doi:10.1007/s10637-005-6735-y
27. Kindler HL, Tothy PK, Wolff R et al. (2005) Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs 23:489-493. doi:10.1007/s10637-005-2909-x
28. Kuznetsov G, TenDyke K, Towle MJ et al. (2009) Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol Cancer Ther 8:2852-2860. doi:10.1158/1535-7163.MCT-09-0301
29. Durrant D, Richard J, Tripathi A et al. (2009) Development of water soluble derivatives of cis-3, 4', 5-trimethoxy-3'-aminostilbene for optimization and use in cancer therapy. Invest New Drugs 27:41-52. doi:10.1007/s10637-008- 9139-y
30. Webb MR. (1992) A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems. Proc Natl Acad Sci U S A 89:4884-4887
31. Wang LG, Liu XM, Kreis W, Budman DR. (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44:355-361
32. Millar JB, McGowan CH, Lenaers G, Jones R, Russell P. (1991) p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. EMBO J 10:4301-4309
33. Lopez-Girona A, Furnari B, Mondesert O, Russell P. (1999) Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 397:172-175. doi:10.1038/16488
34. Gigant B, Wang C, Ravelli RB et al. (2005) Structural basis for the regulation of tubulin by vinblastine. Nature 435:519-522. doi:10.1038/ nature03566
35. Ravelli RB, Gigant B, Curmi PA et al. (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428:198-202. doi:10.1038/nature02393
36. Nunes M, Kaplan J, Wooters J et al. (2005) Two photo affinity analogues of tripeptide, hemiasterlin, exclusively label alpha-tubulin. Biochemistry 44:6844-6857. doi:10.1021/bi0474766
37. Ravi M, Zask A, Rush TS 3rd. (2005) Structure-based identification of the binding site for the hemiasterlin analogue HTI-286 on tubulin. Biochemistry 44:15871-15879. doi:10.1021/bi051268b